Thermo Fisher Scientific ADAR Polyclonal Antibody

Applications

• Immunohistochemistry (Paraffin) (IHC (P)): 1:50–1:100

Product Specifications

Product Specific Information

The antibody detects endogenous levels of total ADAR protein.

Target Information

Adenosine Deaminase RNA Specific (ADAR) catalyzes the hydrolytic deamination of adenosine to inosine in double-stranded RNA (dsRNA), known as A-to-I RNA editing. This process can influence gene expression and function in various ways, including:

• mRNA translation: Alters codons, leading to amino acid substitutions.
• Pre-mRNA splicing: Modifies splice site recognition sequences.
• RNA stability: Affects sequences involved in nuclease recognition.
• Genetic stability: Alters RNA virus genomes during replication.
• RNA structure-dependent activities: Influences microRNA production, targeting, and protein-RNA interactions.

ADAR edits both viral and cellular RNAs, either at multiple sites (hyper-editing) or specific sites (site-specific editing). Known cellular RNA substrates include BLCAP, GRIA2, HTR2C, and GABRA3, where site-specific editing changes amino acid sequences and functional properties.

Viral RNA substrates include HCV, VSV, MV, HDV, and HIV-1. ADAR exhibits proviral or antiviral effects depending on the virus and mechanism (editing-dependent or -independent). It impairs HCV replication through RNA editing while enhancing replication of MV, VSV, and HIV-1 by suppressing EIF2AK2/PKR activation. ADAR also promotes HIV-1 particle release and infectivity via editing in viral RNA regions such as the 5′UTR, Rev, and Tat sequences. In HDV, ADAR-mediated A-to-I editing converts an amber stop codon to a tryptophan codon, enabling synthesis of the large delta antigen essential for viral assembly, though excessive ADAR1 levels inhibit HDV replication.

(Source: UniProt)

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.